Nature | Vol 577 | 16 January 2020 | 425- Grün, D. & van Oudenaarden, A. Design and analysis of single-cell sequencing
experiments. Cell 163 , 799–810 (2015). - Stuart, T. & Satija, R. Integrative single-cell analysis. Nat. Rev. Genet. 20 , 257–272 (2019).
- Risso, D., Perraudeau, F., Gribkova, S., Dudoit, S. & Vert, J. P. A general and flexible method
for signal extraction from single-cell RNA-seq data. Nat. Commun. 9 , 284 (2018). - Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by
pseudotemporal ordering of single cells. Nat. Biotechnol. 32 , 381–386 (2014). - Street, K. et al. Slingshot: cell lineage and pseudotime inference for single-cell
transcriptomics. BMC Genomics 19 , 477 (2018). - Cheung, T. H. & Rando, T. A. Molecular regulation of stem cell quiescence. Nat. Rev. Mol.
Cell Biol. 14 , 329–340 (2013). - Oki, T. et al. A novel cell-cycle-indicator, mVenus–p27K−, identifies quiescent cells and
visualizes G0–G1 transition. Sci. Rep. 4 , 4012 (2014). - Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141 ,
1117–1134 (2010). - Drosten, M. et al. Genetic analysis of Ras signalling pathways in cell proliferation,
migration and survival. EMBO J. 29 , 1091–1104 (2010). - Katayama, H. et al. Phosphorylation by aurora kinase A induces Mdm2-mediated
destabilization and inhibition of p53. Nat. Genet. 36 , 55–62 (2004). - Lim, K. H. et al. Aurora-A phosphorylates, activates, and relocalizes the small GTPase
RalA. Mol. Cell. Biol. 30 , 508–523 (2010).
24. Umstead, M., Xiong, J., Qi, Q., Du, Y. & Fu, H. Aurora kinase A interacts with H-Ras and
potentiates Ras–MAPK signaling. Oncotarget 8 , 28359–28372 (2017).
25. Gong, X. et al. Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor
suppressor gene. Cancer Discov. 9 , 248–263 (2019).
26. Donnella, H. J. et al. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy
in breast cancer. Nat. Chem. Biol. 14 , 768–777 (2018).
27. Shah, K. N. et al. Aurora kinase A drives the evolution of resistance to third-generation
EGFR inhibitors in lung cancer. Nat. Med. 25 , 111–118 (2019).
28. Keen, N. & Taylor, S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4 ,
927–936 (2004).
29. Sunaga, N. et al. Knockdown of oncogenic KRAS in non-small cell lung cancers
suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol. Cancer
Ther. 10 , 336–346 (2011).
30. Fakih, M. et al. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and
efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
J. Clin. Oncol. 37 , 3003 (2019).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
© The Author(s), under exclusive licence to Springer Nature Limited 2020